West Pharmaceutical(US:WST) Prnewswire·2025-06-20 15:45Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against West Pharmaceutical Services, Inc. due to allegations of misleading statements and operational inefficiencies that have negatively impacted the company's financial performance [2][4]. Group 1: Allegations Against West Pharmaceutical Services - The complaint alleges that West and its executives violated federal securities laws by making false and misleading statements regarding customer demand and product performance [4]. - Specific claims include that West was experiencing significant destocking in its High-Value Products portfolio, contrary to its public statements [4]. - The SmartDose device, which was marketed as a high-margin growth product, was actually dilutive to profit margins due to operational inefficiencies [4]. - The company faced risks of costly restructuring activities, including exiting contracts with long-standing customers in the continuous glucose monitoring sector [4]. Group 2: Financial Impact and Stock Performance - The truth about the company's financial struggles was revealed on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025, attributing this to contract manufacturing challenges and the loss of major customers [5]. - Following this announcement, West's stock price plummeted by $123.17 per share, a decline of 38%, closing at $199.11 [5]. Group 3: Legal Proceedings and Investor Actions - Investors who purchased securities in West between February 16, 2023, and February 12, 2025, are encouraged to discuss their legal rights and options with Faruqi & Faruqi [1][2]. - There is a deadline of July 7, 2025, for investors to seek the role of lead plaintiff in the federal securities class action against West [2][6]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding West's conduct [7].